Psychedelic Law 101: What Is Actually Legal in the US?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Anyone trying to understand why psychedelic law is so confusing — whether you’re considering a session, building a business, working in healthcare, or just trying to make sense of what you read in the news.

The short answer

Psychedelic law in the United States is complicated, and the confusion is not your fault. Some psychedelics are legal in some states for some purposes. Others remain fully prohibited under federal law. A few have received FDA designation as breakthrough therapies. One was rejected by the FDA after years of clinical trials. Some cities have decriminalized personal use while their states have not. A small number of religious organizations have won the legal right to use certain substances as sacrament.

None of these categories are the same thing, and none of them mean what most people assume they mean.

This article will not tell you what is legal in your specific situation — that depends on who you are, where you are, and what you are trying to do. It will help you understand enough of the terrain to ask the right questions.

Why people get confused

The core problem is that multiple legal systems govern psychedelics at the same time, and they do not agree with each other.

Federal law — specifically the What is the Controlled Substances Act and how does it affect psychedelics? — classifies most psychedelics as Schedule I controlled substances. That classification means no accepted medical use, high potential for abuse, and illegal to manufacture, distribute, or possess under federal law.

State law operates on a different track. States cannot legalize something under federal law, but they can choose how to enforce their own laws. Oregon and Colorado have created regulated state programs that allow supervised psilocybin services for adults. Several cities have passed decriminalization measures that instruct local police to deprioritize enforcement of personal possession. These are real legal developments, but they exist alongside federal law, not instead of it.

Then there is the FDA track, which governs whether a substance can be developed, studied, and eventually approved as a pharmaceutical treatment. FDA approval and state-program access are entirely different things built on entirely different legal frameworks, and neither one requires the other.

When someone says a psychedelic is “legal,” they usually mean one of these three things — and they often mean the wrong one for their situation. What “legal,” “decriminalized,” “regulated,” and “approved” actually mean breaks down each term precisely.

What the law currently says

Psilocybin is a Schedule I substance under federal law. It remains illegal to possess, manufacture, or distribute under the Controlled Substances Act. Oregon has a regulated state program permitting licensed service centers to administer psilocybin to adults in supervised sessions — no prescription required, but no recreational use either. Colorado has a regulated program currently authorizing psilocybin and psilocin in licensed healing centers; the state has also separately decriminalized personal possession and use of a broader list of natural medicines, but the licensed program is limited to psilocybin and psilocin for now. A number of cities have passed decriminalization resolutions. None of this changes federal law.

MDMA is also Schedule I federally. It was the subject of years of clinical trials for PTSD treatment and received FDA Breakthrough Therapy designation — a designation that accelerated its research path but did not approve it. In August 2024, the FDA issued a Complete Response Letter to Lykos Therapeutics, declining to approve MDMA-assisted therapy for PTSD and citing concerns about trial design, data integrity, and blinding. It is not available through any state program and has no legal pathway to clinical use in the US at this time. What happened with MDMA and the FDA covers this in detail.

Ketamine is a Schedule III controlled substance. Ketamine itself is FDA-approved only as an anesthetic but is widely prescribed off-label by licensed physicians for conditions including depression and PTSD. Esketamine (Spravato), a derivative of ketamine, is FDA-approved as a nasal spray for treatment-resistant depression and is administered in certified clinic settings under a federal safety program. Ketamine infusion clinics and Spravato are the main legal psychedelic-adjacent treatment options currently available to most Americans. Why the law treats these substances differently explains the distinctions in more depth.

Cannabis is Schedule I federally, legal for medical or adult recreational use in a growing number of states. Its legal story is instructive for understanding how state and federal law can diverge, but its specific rules are largely separate from the psychedelic conversation.

Ibogaine and mescaline are Schedule I federally. In Colorado, both are decriminalized for personal use but are not yet part of the licensed regulated program, which is currently limited to psilocybin and psilocin. Neither is part of any current US state licensed program. Some individuals travel internationally to access them.

What changes by state or circumstance

Oregon’s program exists under Oregon law and is administered by the Oregon Health Authority. Adults 21 and older can participate without a prescription, diagnosis, or residency requirement — but only through a licensed service center, with a licensed facilitator, in a supervised session. You cannot take psilocybin home or purchase it outside the regulated system. The program does not provide any protection under federal law.

Colorado’s program is administered jointly by the Department of Regulatory Agencies, which licenses facilitators, and the Department of Revenue’s Natural Medicine Division, which licenses healing centers and related businesses. Licensed healing centers are currently authorized to administer psilocybin and psilocin only. Colorado’s law also separately decriminalizes personal use, possession, and cultivation of ibogaine, DMT, and mescaline (excluding peyote) for adults 21 and older. Like Oregon, supervised sessions at licensed facilities require no prescription or diagnosis.

Outside these two state programs, legal access for most Americans means either a clinical trial or no access at all. The difference between clinical trials and legal access programs explains what that distinction means in practice.

Decriminalization — in cities like Denver, Seattle, Oakland, and others — does not create legal access to any substance. It means local law enforcement has deprioritized enforcement of personal possession. State law and federal law remain unchanged. You can still be prosecuted. You can still face employment, licensing, or professional consequences.

Common mistakes and misconceptions

“It’s legal in Oregon, so I can travel there and bring some back.” Transporting a Schedule I substance across state lines is a federal crime regardless of whether your destination or origin state has decriminalized or regulated it.

“The FDA said it’s a breakthrough therapy, so it must be available.” Breakthrough Therapy designation is a research designation, not an approval. It speeds up the review process. It does not mean a drug is approved, available, or legal to administer. What FDA approval does and does not mean addresses this directly.

“My city decriminalized it, so I’m fine.” Decriminalization reduces local enforcement risk. It does not protect you from state prosecution, federal prosecution, employment drug testing, licensing board scrutiny, or security clearance review. What city-level decriminalization actually means explains the limits.

“I found it in a wellness retreat, so it must be legal.” Operating a wellness retreat does not make a substance legal. Many retreats operate in legal gray zones, offshore, or in outright violation of the law. Some are legitimate. Knowing the difference requires more than a website.

“Research shows it works, so it should be available.” Research findings and legal availability are on separate tracks. A compound can have compelling clinical results and still be fully Schedule I with no legal pathway to access.

When public information may be enough

If you are trying to understand what programs exist, what substances are involved, and how the different legal systems relate to each other, this library is built for that. The Psychedelic legal status by state: a plain-English overview is a good companion to this article.

When you should speak with a lawyer

You should speak with a lawyer when your question has moved from general to specific. That includes:

You are considering starting a business, practice, or spiritual community involving psychedelics
You are a licensed professional — therapist, physician, nurse, attorney, teacher — and want to understand what psychedelic participation or work means for your license
You or someone you care about has been harmed in a psychedelic session
You are a facilitator, retreat operator, or service center trying to understand your legal obligations
You have received a complaint, investigation notice, or legal threat
You are fundraising or taking on investors for a psychedelic venture
You are trying to access services through clinical trials or state programs and your situation is complicated

Do I need a lawyer for my psychedelic question? can help you decide.

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.